
==== Front
J Clin Med
J Clin Med
jcm
Journal of Clinical Medicine
2077-0383
MDPI

10.3390/jcm13113262
jcm-13-03262
Article
A Phase III Head-to-Head Study to Compare the Efficacy and Safety of Fexuprazan and Esomeprazole in Treating Patients with Erosive Esophagitis
Jeong Yuchul Conceptualization Methodology Software Validation Formal analysis Investigation Resources Data curation Writing – original draft Writing – review & editing Visualization Funding acquisition 1
Lee Beom Jun Conceptualization Methodology Software Validation Formal analysis Investigation Resources Data curation Writing – original draft Writing – review & editing Visualization Funding acquisition 2
https://orcid.org/0000-0002-1681-7029
Han Se-Hyeon Conceptualization Methodology Software Validation Formal analysis Investigation Resources Data curation Writing – original draft Writing – review & editing Visualization Supervision Project administration Funding acquisition 3*
Gingold-Belfer Rachel Academic Editor
1 Department of Internal Medicine, Chungna Good Hospital, Incheon 22738, Republic of Korea
2 St. Mary’s Best ENT Clinic, Seoul 08849, Republic of Korea
3 Department of Companion Animal Industry, College of Health Science, Honam University, Gwangju 62399, Republic of Korea
* Correspondence: han382@gmail.com
31 5 2024
6 2024
13 11 326216 3 2024
19 5 2024
22 5 2024
© 2024 by the authors.
2024
https://creativecommons.org/licenses/by/4.0/ Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Background: Fexuprazan (Fexuclue®; Daewoong Pharmaceutical Co., Ltd., Seoul, Korea) is a novel potassium-competitive acid blocker (P-CAB). This multi-center, randomized, double-blind, active-controlled, parallel-group, therapeutic confirmatory, phase III study was conducted to assess its efficacy and safety compared with esomeprazole (Nexium®; AstraZeneca, Gothenburg, Mölndal, Sweden) in Korean patients with erosive esophagitis (EE). Methods: This study evaluated patients diagnosed with EE at a total of 25 institutions in Korea between 13 December 2018 and 7 August 2019. After voluntarily submitting a written informed consent form, the patients were evaluated using a screening test and then randomized to either of the two treatment arms. The proportion of the patients who achieved the complete recovery of mucosal breaks at 4 and 8 weeks, the proportion of those who achieved the complete recovery of heartburn at 3 and 7 days and 8 weeks, and changes in the GERD–Health-Related Quality of Life Questionnaire (GERD-HRQL) scores at 4 and 8 weeks from baseline served as efficacy outcome measures. The incidence of treatment-emergent adverse events (TEAEs) and adverse drug reactions (ADRs) and the serum gastrin levels served as safety outcome measures. Results: The study population comprised a total of 231 patients (n = 231) with EE, including 152 men (65.80%) and 79 women (34.20%); their mean age was 54.37 ± 12.66 years old. There were no significant differences in the efficacy and safety outcome measures between the two treatment arms (p > 0.05). Conclusions: It can be concluded that the efficacy and safety of Fexuclue® are not inferior to those of esomeprazole in Korean patients with EE.

gastroesophageal reflux
esophagitis
proton pump inhibitors
heartburn
quality of life
Daewoong Pharmaceutical Co., Ltd., Seoul, KoreaDWP14012 The current study was sponsored by Daewoong Pharmaceutical Co., Ltd., Seoul, Korea (DWP14012).
==== Body
pmc1. Introduction

Gastroesophageal reflux disease (GERD) is a common disease entity that affects people in Western countries. Recently, there has been an increased incidence of GERD; approximately 1/3 of adults present with its symptoms [1]. By contrast, its incidence in East Asian countries is much lower compared with Western ones; here, its incidence ranges between 3% and 7% in people presenting with heartburn or acid regurgitation at least weekly [2,3]. Due to rapid westernization, GERD is occurring more frequently in Korea [4].

The occurrence of GERD is closely associated with the abnormal reflux of gastric contents into the esophagus, and its specific symptoms include heartburn and acid regurgitation [5]. But patients with GERD do not belong to a homogenous group; GERD can be classified into erosive esophagitis (EE) and non-erosive reflux disease (NERD), depending on the existence of esophageal mucosal breaks on esophagogastroduodenoscopy (EGD). EE, characterized by mucosal breaks, accounts for only 1/3–1/2 of total patients with GERD [6].

The inhibition of gastric acid secretion is an effective strategy in patients with GERD, peptic ulcers, and low-dose aspirin (LDA) or non-steroidal anti-inflammatory drug (NSAID)-induced peptic ulcers [7,8]. Proton pump inhibitors (PPIs) first appeared in the late 1980s. Since then, PPIs have often been used to treat patients with acid-related diseases. Conventional types of PPIs are characterized by a benzimidazole structure, whose mode of action is based on the irreversible inhibition of hydrogen potassium (H+, K+)-ATPases [9,10]. One of the hormones of the gastrointestinal system, gastrin, is released by the G cells of the antrum of the stomach. It plays a role in stimulating gastric acid secretion [11]. The monitoring of serum gastrin levels is mandatory for GERD that is refractory to proton pump inhibitors (PPIs). It is characterized by abnormal gastrin production, which is defined as serum gastrin levels > 100–150 pg/mL [12]. Therefore, if elevated, they should be checked and the relevant source should be identified [11].

To date, the use of PPIs has been a mainstream modality, although they have revealed the following disadvantages: First, the treatment effects are maximized after several days of treatment. Second, the treatment effects of PPIs depend on the cytochrome P450 (CYP) 2C19 polymorphism. Third, their treatment effects during the night are unsatisfactory. Fourth, they require an enteric coating because PPIs are unstable in the acidic environment that is needed for their activation [13,14]. Moreover, concerns have been recently raised regarding a causal relationship between the long-term use of PPIs and adverse drug reactions (ADRs), such as fracture, hypomagnesaemia, interstitial nephritis, iron and vitamin B12 malabsorption and infections [15]. In particular, fracture was considered a serious ADR, such that the US Food and Drug Administration (FDA) issued a letter warning that patients receiving PPIs for long periods of time are vulnerable to fractures in the distal femur, spine and distal forearm [15,16].

To overcome the above-mentioned problems of PPIs, potassium-competitive acid blockers (P-CABs) have been developed as alternative treatment modalities that can fulfill the unmet needs of patients who are not satisfied with the treatment outcomes of PPIs [17].

Since the emergence of P-CABs, considerable efforts have been made to compare the efficacy and safety between them and PPIs. But this has led to studies showing variable and conflicting results [18,19,20,21,22,23,24,25].

Esomeprazole (Nexium®; AstraZeneca, Gothenburg, Mölndal, Sweden) is a PPI whose healing effect was previously documented [26].

Fexuprazan (Fexuclue®; Daewoong Pharmaceutical Co., Ltd., Seoul, Korea) is a novel P-CAB [27,28,29,30,31,32,33,34]. According to a preclinical experiment comparing between fexuprazan and vonoprazan, the former was effective in inhibiting acid secretion in a dose-dependent manner and the degree of its inhibitory effect was equivalent to or higher than that of the latter [34]. Moreover, Sunwoo et al. reported that fexuprazan was a well-tolerated drug showing rapid and long-lasting effects during the inhibition of gastric acid secretion [34].

Given the above background, this multi-center, randomized, double-blind, active-controlled, parallel-group, therapeutic confirmatory, phase III study was conducted to compare the efficacy and safety of fexuprazan and esomeprazole in Korean patients with EE.

2. Patients and Methods

2.1. Study Setting and Ethics Statement

This study evaluated patients diagnosed with EE at a total of 25 institutions in Korea between 13 December 2018 and 7 August 2019. The inclusion/exclusion criteria are presented in Table 1.

This study was approved by the Internal Institutional Review Board (IRB) of the respective institutions involved in it and then conducted in compliance with the relevant ethics guidelines. All the study treatments and procedures described herein were performed in accordance with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. All the patients submitted a written informed consent form. The current study is registered with ClinicalTrials.gov (NCT03736369).

2.2. Rationale of Sample Size Estimation

According to Labenz et al. and Richter et al., the proportion of patients who achieved the complete recovery of mucosal breaks within 8 weeks in the esomeprazole 40 mg group was 95.5% and 93.7%, respectively [35,36]. Based on previously published studies showing that the lower limit (LL) of the non-inferiority margin was set at −0.1, we also used the same LL for the current study [18,37,38].

Considering an LL of a non-inferiority margin of −0.1, a one-sided level of statistical significance of 2.5%, a test power of 90% and a randomization ratio of 1:1, we estimated the sample size to be 104 per group with the use of the Power Analysis and Sample Size software (PASS) program (version 2020), as described in “Non-Inferiority Tests for the Difference Between Two Proportions”. But this study conservatively hypothesized that 20% of the total patients would be excluded from the PPS. The sample size was therefore estimated at 260 (130 per group).

2.3. Randomization and Study Treatments

The patients were randomized to either of the two treatment arms at a ratio of 1:1 using the PROC PLAN procedure in SAS Software Version 9.4 (SAS Institute, Cary, NC, USA) and the interactive web response system (IWRS).

From the next day of randomization, the patients were given a QD regimen of two tablets of study treatments (fexuprazan 40 mg or its matching placebo in the trial group and esomeprazole 40 mg or its matching placebo in the control group) for four weeks. The dosing rationale was based on previously published studies in this series [34,39,40]. To ensure that the double-blind design was maintained throughout the treatment period, investigational products were administered in a double dummy manner. The study schema is shown in Figure 1.

One week after the study treatments, the patients were evaluated using a telephone interview. At 4 weeks, they visited the study center and were evaluated for whether the lesion had healed on EGD. Two weeks after the healing of the lesion had been confirmed, the patients visited the study center for a safety assessment. But the patients whose healing was not confirmed were given the study treatments for another four weeks. Then, they visited the study center and were evaluated for whether the lesion had healed on EGD. Two weeks after the healing of the lesion had been confirmed, the patients were evaluated in a safety assessment using a telephone interview, and, if applicable, they received additional tests and procedures.

2.4. Patient Evaluation and Criteria

The baseline characteristics of the patients include age, sex, body mass index (BMI), smoking history, drinking history, LA grade, H. pylori infections and CYP2C19 extensive metabolizer (EM)/poor metabolizer (PM).

The patients were assigned to the full analysis set (FAS), comprising those receiving study treatments at least once, and the per protocol set (PPS), comprising those completing the current study without protocol violation. Then, the proportion of the patients who achieved the complete recovery of heartburn within the first 3 and 7 days and throughout the 8 weeks served as efficacy outcome measures. Moreover, changes in the GERD–Health-Related Quality of Life Questionnaire (GERD-HRQL) scores at 4 and 8 weeks from baseline served as secondary efficacy outcome measures. The GERD-HRQOL is an 11-item self-administered questionnaire that was developed to examine symptomatic the outcomes and therapeutic effects in patients with GERD, which focuses on heartburn, dysphagia, medication effects and health conditions [41].

The incidence of treatment-emergent adverse events (TEAEs) and adverse drug reactions (ADRs) and the serum gastrin levels served as the safety outcome measures.

2.5. Statistical Analysis of the Patient Data

All data were expressed as mean ± SD (SD: standard deviation), mean ± SE (SE: standard error of the mean), median with the range or the number of patients with percentage, where appropriate.

For efficacy assessment, differences in the efficacy outcome measures were compared between the two treatment arms; for this, the Cochran–Mantel–Haenszel (CMH) test, adjusting for the baseline LA grade, was performed, and the lower limit (LL) of the two-sided 95% CIs was calculated accordingly. At the LL of a non-inferiority margin of >−0.1, the trial group was determined to be significantly inferior to the control group. Otherwise, differences in the least squares mean (LSM) of measurements were calculated using the analysis of covariance (ANCOVA) model, adjusting for the baseline LA grade, which served as a covariate, and then compared between the two treatment arms, for which two-sided 95% CIs were provided.

For the safety assessment, differences in the safety outcome measures were compared between the two treatment arms, for which χ2- or Fisher’s exact tests were performed. All statistical analyses were performed using the SPSS ver. 23 (IBM corp., Armonk, NY, USA). A p-value of <0.05 was considered statistically significant.

3. Results

3.1. Baseline Characteristics of the Patients

The study population comprised a total of 231 patients (n = 231) with EE, including 152 men (65.80%) and 79 women (34.20%); their mean age was 54.37 ± 12.66 years old. There were no significant differences in the baseline characteristics between the two treatment arms. The baseline characteristics of the patients are presented in Table 2.

The disposition of the study patients is shown in Figure 2.

A total of 263 patients were randomized to either of the two treatment arms, 231 of whom met the inclusion/exclusion criteria and were given both study treatments and EGD more than once. These 231 patients were assigned to the FAS. Of these, 218 patients completed the current study without serious protocol violation and were assigned to the PPS. Moreover, a total of 263 patients were randomized to either of the two treatment arms, one (0.38%) of whom did not receive study treatments. Therefore, the remaining 262 patients (99.62%) received study treatments more than once and were assigned to the safety set.

3.2. Efficacy Outcomes

As shown in Table 3, there were no significant differences in the efficacy outcome measures between the two treatment arms (p > 0.05). Moreover, the CC healing rate at 4 and 8 weeks is shown in Figure 3.

At 4 weeks, the EE healing rate was 90.3% (93/103) in the fexuprazan 40 mg group and 88.5% (92/104) in the esomeprazole 40 mg group. At 8 weeks, it was 99.1% (106/107) and 99.1% (110/111) in the corresponding order. These results indicate that there was no significant difference in the EE healing rate at 4 and 8 weeks between the two treatment arms (p > 0.05).

Following a comparison of the efficacy profile between the two treatment arms, it can be inferred that the fexuprazan 40 mg group is not inferior to the esomeprazole 40 mg group.

3.3. Safety Outcomes

As shown in Table 4, there were no significant differences in the safety outcome measures between the two treatment arms (p > 0.05). Moreover, the time-dependent changes in the serum gastrin levels are shown in Figure 4.

Changes in the serum gastrin levels at 4 and 8 weeks from baseline were presented as the least square mean with 95% confidence intervals; they were measured as 21.37 pg/mL (−4.98–47.72) in the fexuprazan 40 mg group and 22.08 pg/mL (−2.68–46.83) in the esomeprazole 40 mg group. But this difference reached no statistical significance (p > 0.05).

Following a comparison of the safety profile between the two treatment arms, it can be inferred that the fexuprazan 40 mg group is not inferior to the esomeprazole 40 mg group.

4. Discussion

According to the current practical guidelines for patients with EE, PPIs are recommended as a first-line therapy and surgery is also recommended for those with resistance to PPIs [42]. Despite the extensive use of PPIs in the clinical setting, their standard dose cannot guarantee a sufficient level of gastric acid suppression because of the pharmacological limitations [43,44]. This explains the need to further explore P-CABs that are appropriate for patients with EE.

Vonoprazan (Takecab®; Takeda Pharmaceutical Company Ltd., Osaka, Japan) is a novel P-CAB that was first developed and then compared to PPIs; its efficacy and safety are not inferior to those of PPIs [18,19,45,46,47]. Two novel P-CABs have also been developed in Korea. Of these, tegoprazan was also compared with a PPI; the efficacy and tolerability of the QD regimen of tegoprazan 50 or 100 mg were not inferior to those of esomeprazole 40 mg in patients with EE [20].

Patients with EE may exhibit diverse symptoms, including heartburn and acid regurgitation, that may impair the HR-QOL [48,49,50,51]. In more detail, the frequency and severity of symptoms rather than the presence of esophagitis are closely associated with a poor HR-QOL [52]. The current results showed that there were no significant differences in the GERD-HRQL scores between the two treatment arms.

In this study, the patients receiving fexuprazan 40 mg achieved the complete healing of heartburn more rapidly, with the more rapid onset of action compared with esomeprazole 40 mg. This deserves special attention because approximately 80% of patients presenting with frequent heartburn also complain of nocturnal heartburn [53,54]. Thus, nocturnal reflux with nocturnal acid breakthrough may impair sleep quality and daytime QOL. More than 30% of patients taking PPIs due to reflux esophagitis accompanied by heartburn continuously suffer from nocturnal heartburn [55]. Therefore, it remains problematic that more than 50% of patients with symptomatic EE taking PPIs are refractory to the treatment [56].

It is evident that both P-CAB and PPIs lower the gastric acid levels in the stomach by prompting the secretion of gastrin from antral G cells [57]. Indeed, according to Echizen, H, P-CAB was more effective in inhibiting the secretion of gastric acid compared with PPIs; the former caused 2- to 3-fold higher serum gastrin levels compared with the latter [58]. In more detail, Kojima Y, et al. showed that the median serum gastrin levels were significantly higher in individuals receiving P-CAB compared with those receiving PPIs after the long-term administration of both drugs (870 [range, 120–3000] vs. 440 [87–2000] pg/mL, respectively; p > 0.05) [59]. In this study, however, there were no significant differences in the serum gastrin levels between the two treatment arms.

The limitations of this study are as follows: First, this study failed to consider the possible effects of comorbidities that may affect the severity of EE, such as chronic heart failure or chronic obstructive pulmonary disease [60,61]. Second, this study failed to assess the long-term safety of fexuprazan in patients with EE. As described earlier, the long-term use of PPIs had a significant correlation with ADRs [15]. Still, however, there is a paucity of data suggesting the long-term safety of P-CABs. This deserves further long-term follow-up studies. Fourth, this study enrolled a relatively smaller number of patients classified as LA grade C/D; it has been reported that those with LA grade A/B account for more than 90% of total cases [62]. Fifth, this study failed to consider lifestyle factors that may affect the symptoms of EE when comparing the GERD-HRQL scores between the two treatment arms. This deserves further studies using the Quality of Life and Utility Evaluation Survey Technology Questionnaire (QUEST), Manterola’s Scale, Frequency Scale for the Symptoms of GERD (FSSG) or Zimmerman’s Scale [63].

As a heterogeneous group of drugs, P-CABs inhibit the actions of H+, K+ ATPase in a potassium-competitive reversible manner. Their advantages include not needing to activate proton pump, the rapid onset of their action and the steady elevation of their plasma levels, leading to a decrease in acid secretion [17,28].

Based on the current results, it can be concluded that the efficacy and safety of fexuprazan are not inferior to those of esomeprazole in Korean patients with EE. Of note, however, the patients receiving fexuprazan 40 mg achieved the complete healing of heartburn more rapidly compared with the esomeprazole 40 mg group. In addition, there were no significant differences in the serum gastrin levels between the two treatment arms. But further experimental studies are warranted to clarify the potential mechanisms underlying the therapeutic benefits of fexuprazan; a previous study showed that the effects of P-CAB are linked to microinflammation, a dilated intercellular space and visceral hypersensitivity [64]. Moreover, further studies are also needed to clarify the reasons for the rapid symptomatic improvement in patients who were using fexuprazan compared with esomeprazole.

Acknowledgments

The authors thank Laon Medi Solution Inc. (Seoul, Republic of Korea) and KDH Medical Inc. (Gwangmyeong, Gyeonggi, Republic of Korea) for providing additional support of this research.

Author Contributions

Conceptualization, Y.J., B.J.L. and S.-H.H.; data curation, Y.J., B.J.L. and S.-H.H.; formal analysis, Y.J., B.J.L. and S.-H.H.; funding acquisition, Y.J., B.J.L. and S.-H.H.; investigation, Y.J., B.J.L. and S.-H.H.; methodology, Y.J., B.J.L. and S.-H.H.; project administration, S.-H.H.; resources, Y.J., B.J.L. and S.-H.H.; software, Y.J., B.J.L. and S.-H.H.; supervision, S.-H.H.; validation, Y.J., B.J.L. and S.-H.H.; visualization, Y.J., B.J.L. and S.-H.H.; writing—original draft, Y.J., B.J.L. and S.-H.H.; writing—review and editing, Y.J., B.J.L. and S.-H.H. All authors have read and agreed to the published version of the manuscript.

Institutional Review Board Statement

This study was approved by the Internal Institutional Review Board (IRB) of the respective institutions involved in it and then conducted in compliance with the relevant ethical guidelines.

Informed Consent Statement

All the patients submitted a written informed consent.

Data Availability Statement

The data presented in this study are available upon request from the corresponding author. The data are not publicly available due to privacy reasons.

Conflicts of Interest

The authors declare no conflicts of interest.

Figure 1 Study schema.

Figure 2 Disposition of the study patients.

Figure 3 Erosive esophagitis (EE) healing rate at 4 and 8 weeks.

Figure 4 Time-dependent changes in serum gastrin levels.

jcm-13-03262-t001_Table 1 Table 1 Eligibility criteria.

Criteria for Selecting the Patients in the Current Study.	
Inclusion criteria(1) Men or women aged between 20 and 75 years old

(2) Patients who had been diagnosed with EE of LA Grade C/D on EGD at the same institution within 14 days of the initiation of study treatments.

	
Exclusion criteria(1) Patients who had been diagnosed with Barrett’s esophagus (>3 cm), esophageal varices, esophageal stricture, peptic ulcer-related stenosis, active peptic ulcer, gastrointestinal bleeds and/or a malignant tumor on EGD at screening

(2) Patients with inflammatory bowel diseases (e.g., Crohn’s disease and ulcerative colitis), IBS, primary esophageal motility disorder and/or pancreatitis

(3) Patients with a past history of taking gastric acid suppression therapy and/or gastroesophageal surgery, such as gastrectomy or gastric mucosal resection, other than appendectomy, cholecystectomy or endoscopic-assisted resection of the benign tumor

(4) Patients with signs and symptoms such as odynophagia, severe dysphagia, bleeding, weight loss, anemia or hematochezia, which are suggestive of gastrointestinal malignancies

(5) Patients with Zollinger–Ellison syndrome

(6) Patients with eosinophilic esophagitis

(7) Patients with clinically notable abnormalities in the liver, kidney, neurologic system, respiratory system, endocrine system, hemato-oncologic system, cardiovascular system and urologic system

(8) Patients with a past history of malignancies within the past five years

(9) Patients with psychiatric disorder

(10) Patients with a past history of drug or alcohol abuse

(11) Patients with AIDS, HBs antigen-positive or HCV antibody-positive hepatitis or those with viral carriers

(12) Patients with hypersensitivity reactions or a past history of clinically notable hypersensitivity to drugs containing active constituents of esomeprazole or other similar drugs (e.g., benzimidazoles and antibiotics)

(13) Patients who were given any drugs that may affect the results of the current study; these include NSAIDs, acetaminophen, anti-gastric secretion drugs (e.g., PPIs, acid pump antagonists, H2 receptor antagonists and anti-gastrin agents), cholinergic or anti-cholinergic drugs, sedatives, anti-psychiatric drugs (e.g., anti-psychotic drugs, anti-depressants, anti-manic drugs, anxiolytics and hallucinogens), corticosteroids for systemic use, anti-thrombotic agents (e.g., anti-platelet agents and anti-coagulants), prokinetics, mucosa-protective agents and antacids (e.g., aluminium hydroxide, magnesium hydroxide, calcium carbonate and sodium bicarbonate)

(14) Patients who were in need of any treatments using prohibited concomitant medications during the conduct of the current study

(15) Patients with a past history of taking treatments for other trials within four weeks prior to study treatments

(16) Patients whose serum levels of ALT, AST, ALP, γ-GT, total bilirubin, creatinine and BUN were elevated by >2 × ULN

(17) Women who are pregnant or breastfeeding

(18) Patients, or their partners, who did not consent to the use of appropriate contraceptive methods during the conduct of the current study

(19) Patients who are contraindicated in EGD

(20) Patients who are deemed ineligible for study participation according to our judgment.

	
Abbreviations: EE, erosive esophagitis; LA, Los-Angeles; EGD, esophagogastroduodenoscopy; IBS, irritable bowel syndrome; AIDS, acquired immune deficiency syndrome; HBs, hepatitis B surface; HCV, hepatitis C virus; NSAIDs, non-steroidal anti-inflammatory drugs; PPIs, proton pump inhibitors; ALT, alanine aminotransferase; AST, aspartate transaminase; ALP, alkaline phosphatase; γ-GT, γ-glutamyl transpeptidase; BUN, blood urine nitrogen; ULN, upper limit of the normal.

jcm-13-03262-t002_Table 2 Table 2 Baseline characteristics of the patients.

Variables	Values	p-Value	
Fexuprazan 40 mg
(n = 116)	Esomeprazole 40 mg
(n = 115)	
Age (years)	53.70 ± 12.44	55.05 ± 12.05	0.3428 a	
Sex	
	Men	78 (67.24%)	74 (64.35%)	0.6430 b	
Women	38 (32.76%)	41 (35.65%)	
BMI (kg/m2)	24.42 ± 3.08	24.81 ± 3.25	0.5293 a	
Smoking history	
	Non-smokers	67 (57.76%)	66 (57.39%)	0.9782 b	
Current smokers	25 (21.55%)	26 (22.61%)	
Past smokers	24 (20.69%)	23 (20.00%)	
Drinking history	
	Non-drinkers	15 (12.93%)	15 (13.04%)	0.9916 b	
Current drinkers	77 (66.38%)	77 (66.96%)	
Past drinkers	24 (20.69%)	23 (20.00%)	
LA grade	
	Grade A	75 (64.66%)	76 (66.09%)	0.6303 b	
Grade B	33 (28.45%)	31 (26.96%)	
Grade C	6 (5.17%)	8 (6.96%)	
Grade D	2 (1.72%)	0 (0.00%)	
Helicobacter pylori	
	Positive	20 (17.39%)	31 (27.19%)	0.0747 b	
Negative	95 (82.61%)	83 (72.81%)	
CYP2C19	
	EM	39 (76.47%)	53 (94.64%)	0.0068 b	
PM	12 (23.53%)	3 (5.36%)	
Abbreviations: BMI, body mass index; LA, Los Angeles; CYP2C19, cytochrome P 2C19; EM, extensive metabolizer; PM, poor metabolizer. Values are mean ± standard deviation or the number of the patients with percentage, where appropriate. a Two-sample t-test or Wilcoxon rank-sum test. b χ2-test or Fisher’s exact test.

jcm-13-03262-t003_Table 3 Table 3 Efficacy outcomes.

Variables	Values	p-Value	
Fexuprazan 40 mg	Esomeprazole 40 mg	
Primary efficacy outcome measures	
% of CR for the first 3 days	30.84% (33/107) (22.09–39.59)	23.42% (26/111) (15.54–31.30)	0.1997 a	
% of CR for the first 7 days	26.17% (28/107) (17.84–34.50)	21.62% (24/111) (13.96–23.28)	0.3957 a	
% of CR throughout 8 weeks	20.56% (22/107) (12.90–28.22)	17.12 (19/111) (10.11–24.12)	0.4842 a	
Secondary efficacy outcome measures	
Changes in GERD-HRQL scores at 4 and 8 weeks from baseline	−7.90 ± 8.56 (−8.34 ± 1.07) (n = 106)	−9.67 ± 8.56 (−9.39 ± 1.12) (n = 111)	0.1509 b	
Abbreviations: CR, complete remission; GERD-HRQL, GERD–Health-Related Quality of Life Questionnaire. Values are percentage with 95% confidence intervals or mean ± standard deviation with least square mean ± standard error, where appropriate. a Cochran–Mantel–Haenszel test. b Analysis of covariance.

jcm-13-03262-t004_Table 4 Table 4 Safety outcomes.

Variables	Values	p-Value	
Fexuprazan
40 mg
(n = 131)	Esomeprazole
40 mg
(n = 131)	
Incidence of TEAEs by MedDRA SOC and PT	22 (16.79%)	25 (19.08%)	0.629	
Incidence of ADRs by MedDRA SOC and PT	9 (6.87%)	7 (5.34%)	0.606	
Changes in serum gastrin levels at 4 and 8 weeks from baseline (pg/mL)	21.37 (−4.98–47.72)	22.08 (−2.68–46.83)	0.724	
Abbreviations: TEAEs, treatment-emergent adverse events; MedDRA, Medical Dictionary for Regulatory Activities; SOC, System Organ Class; PT, Preferred Terms; ADRs, adverse drug reactions. Values are the number of the patients with percentage or least square mean with 95% confidence intervals, where appropriate.

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
==== Refs
References

1. Clarrett D.M. Hachem C. Gastroesophageal Reflux Disease (GERD) Mo. Med. 2018 115 214 218 30228725
2. Ho K.U. Gastroesophageal Reflux Disease Is Uncommon in Asia: Evidence and Possible Explanations World J. Gastroenterol. 1999 5 4 6 10.3748/wjg.v5.i1.4 11819371
3. Lee J.H. Park J.M. Han S.U. Kim J.J. Song K.Y. Ryu S.W. Seo K.W. Kim H.I. Kim W. Korean Antireflux Surgery Study (KARS) Group Antireflux Surgery in Korea: A Nationwide Study from 2011 to 2014 Gut Liver 2016 10 726 730 10.5009/gnl15406 27114420
4. Giorgi F.D. Palmiero M. Esposito I. Mosca F. Cuomo R. Pathophysiology of Gastro-Oesophageal Reflux Disease Acta Otorhinolaryngol. Ital. 2006 26 241 246 17345925
5. Ha N.R. Lee H.L. Lee O.Y. Yoon B.C. Choi H.S. Hahm J.S. Ahn Y.H. Koh D.H. Differences in Clinical Characteristics Between Patients with Non-Erosive Reflux Disease and Erosive Esophagitis in Korea J. Korean Med. Sci. 2010 25 1318 1322 10.3346/jkms.2010.25.9.1318 20808675
6. Deppe H. Mücke T. Wagenpfeil S. Kesting M. Rozej A. Bajbouj M. Sculean A. Erosive esophageal reflux vs. non erosive esophageal reflux: Oral findings in 71 patients BMC Oral Health 2015 15 84 10.1186/s12903-015-0069-8 26208714
7. Cryer B. Mahaffey K.W. Gastrointestinal Ulcers, Role of Aspirin, and Clinical Outcomes: Pathobiology, Diagnosis, and Treatment J. Multidiscip. Healthc. 2014 7 137 146 10.2147/JMDH.S54324 24741318
8. Lanas A. Gargallo C.J. Management of Low-Dose Aspirin and Clopidogrel in Clinical Practice: A Gastrointestinal Perspective J. Gastroenterol. 2015 50 626 637 10.1007/s00535-015-1038-3 25595209
9. Shin J.M. Sachs G. Pharmacology of Proton Pump Inhibitors Curr. Gastroenterol. Rep. 2008 10 528 534 10.1007/s11894-008-0098-4 19006606
10. Shin J.M. Sachs G. Long Lasting Inhibitors of the Gastric H,K-ATPase Expert Rev. Clin. Pharmacol. 2009 2 461 468 10.1586/ecp.09.33 21132072
11. Camilleri M. Gastrointestinal hormones and regulation of gastric emptying Curr. Opin. Endocrinol. Diabetes Obes. 2019 26 3 10 10.1097/MED.0000000000000448 30418188
12. Berna M.J. Hoffman K.M. Serrano J. Gibril F. Jensen R.T. Serum gastrin in Zollinger-Ellison syndrome: I. Prospective study of fasting serum gastrin in 309 patients from the National Institutes of Health and comparison with 2229 cases from the literature Medicine 2006 85 295 330 10.1097/01.md.0000236956.74128.76 17108778
13. Rouby N.E. Lima J.J. Johnson J.A. Proton Pump Inhibitors: From CYP2C19 Pharmacogenetics to Precision Medicine Expert Opin. Drug Metab. Toxicol. 2018 14 447 460 10.1080/17425255.2018.1461835 29620484
14. Horn J. Review Article: Relationship Between the Metabolism and Efficacy of Proton Pump Inhibitors–Focus on Rabeprazole Aliment. Pharmacol. Ther. 2004 20 (Suppl. 6) 11 19 10.1111/j.1365-2036.2004.02161.x 15496214
15. Vakil N. Prescribing proton pump inhibitors: Is it time to pause and rethink? Drugs 2012 72 437 445 10.2165/11599320-000000000-00000 22356286
16. Wang L. Li M. Cao Y. Han Z. Wang X. Atkinson E.J. Liu H. Amin S. Proton Pump Inhibitors and the Risk for Fracture at Specific Sites: Data Mining of the FDA Adverse Event Reporting System Sci. Rep. 2017 7 5527 10.1038/s41598-017-05552-1 28717153
17. Rawla P. Sunkara T. Ofosu A. Gaduputi V. Potassium-competitive Acid Blockers—Are They the Next Generation of Proton Pump Inhibitors? World J. Gastrointest. Pharmacol. Ther. 2018 9 63 68 10.4292/wjgpt.v9.i7.63 30595950
18. Ashida K. Sakurai Y. Hori T. Kudou K. Nishimura A. Hiramatsu N. Umegaki E. Iwakiri K. Randomised Clinical Trial: Vonoprazan, a Novel Potassium-Competitive Acid Blocker, vs. Lansoprazole for the Healing of Erosive Oesophagitis Aliment. Pharmacol. Ther. 2016 43 240 251 10.1111/apt.13461 26559637
19. Ashida K. Iwakiri K. Hiramatsu N. Sakurai Y. Hori T. Kudou K. Nishimura A. Umegaki E. Maintenance for Healed Erosive Esophagitis: Phase III Comparison of Vonoprazan with Lansoprazole World J. Gastroenterol. 2018 24 1550 1561 10.3748/wjg.v24.i14.1550 29662293
20. Lee K.J. Son B.K. Kim G.H. Jung H.K. Jung H.Y. Chung I.K. Sung I.K. Kim J.I. Kim J.H. Lee J.S. Randomised Phase 3 Trial: Tegoprazan, a Novel Potassium-Competitive Acid Blocker, vs. Esomeprazole in Patients with Erosive Oesophagitis Aliment. Pharmacol. Ther. 2019 49 864 872 10.1111/apt.15185 30843245
21. Iwakiri K. Sakurai Y. Shiino M. Okamoto H. Kudou K. Nishimura A. Hiramatsu N. Umegaki E. Ashida K. A randomized, double-blind study to evaluate the acid-inhibitory effect of vonoprazan (20 mg and 40 mg) in patients with proton-pump inhibitor-resistant erosive esophagitis Therap. Adv. Gastroenterol. 2017 10 439 451 10.1177/1756283X17705329
22. Shinozaki S. Osawa H. Hayashi Y. Sakamoto H. Miura Y. Lefor A.K. Yamamoto H. Vonoprazan treatment improves gastrointestinal symptoms in patients with gastroesophageal reflux disease Kaohsiung J. Med. Sci. 2017 33 616 622 10.1016/j.kjms.2017.07.004 29132551
23. Hunt R.H. Scarpignato C. Potassium-competitive acid blockers (PCABs): Are they finally ready for prime time in acid-related disease Clin. Transl. Gastroenterol. 2015 6 e119 10.1038/ctg.2015.39 26513137
24. Murakami K. Sakurai Y. Shiino M. Funao N. Nishimura A. Asaka M. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: A phase III, randomised, double-blind study Gut 2016 65 1439 1446 10.1136/gutjnl-2015-311304 26935876
25. Kinoshita Y. Sakurai Y. Shiino M. Kudou K. Nishimura A. Miyagi T. Iwakiri K. Umegaki E. Ashida K. Evaluation of the efficacy and safety of vonoprazan in patients with nonerosive gastroesophageal reflux disease: A phase iii, randomized, double-blind, placebo-controlled, multicenter study Curr. Ther. Res. Clin. Exp. 2016 81–82 1 7
26. Kahrilas P.J. Falk G.W. Johnson D.A. Schmitt C. Collins D.W. Whipple J. D’Amico D. Hamelin B. Joelsson B. Esomeprazole Improves Healing and Symptom Resolution as Compared With Omeprazole in Reflux Oesophagitis Patients: A Randomized Controlled Trial. The Esomeprazole Study Investigators Aliment. Pharmacol. Ther. 2000 14 1249 1258 10.1046/j.1365-2036.2000.00856.x 11012468
27. Sachs G. Marcus E.A. Wen Y. Munson K. Editorial: Control of Acid Secretion Aliment. Pharmacol. Ther. 2018 48 682 683 10.1111/apt.14864 30132940
28. Scarpignato C. Hunt R.H. Editorial: Potassium-Competitive Acid Blockers for Acid-Related Diseases-Tegoprazan, a New Kid on the Block Aliment. Pharmacol. Ther. 2019 50 960 962 10.1111/apt.15480 31591775
29. Shibli F. Kitayama Y. Fass R. Novel Therapies for Gastroesophageal Reflux Disease: Beyond Proton Pump Inhibitors Curr. Gastroenterol. Rep. 2020 22 16 10.1007/s11894-020-0753-y 32185589
30. Hunt R.H. Scarpignato C. Potent Acid Suppression with PPIs and P-CABs: What’s New? Curr. Treat. Options Gastroenterol. 2018 16 570 590 10.1007/s11938-018-0206-y 30361857
31. Oshima T. Miwa H. Potent Potassium-competitive Acid Blockers: A New Era for the Treatment of Acid-related Diseases J. Neurogastroenterol. Motil. 2018 24 334 344 10.5056/jnm18029 29739175
32. O’Connor A. Liou J.M. Gisbert J.P. O’Morain C. Review: Treatment of Helicobacter Pylori Infection 2019 Helicobacter 2019 24 (Suppl. S1) e12640 10.1111/hel.12640 31486235
33. Mori H. Suzuki H. Role of Acid Suppression in Acid-related Diseases: Proton Pump Inhibitor and Potassium-competitive Acid Blocker J. Neurogastroenterol. Motil. 2019 25 6 14 10.5056/jnm18139 30504527
34. Sunwoo J. Oh J. Moon S.J. Ji S.C. Lee S.H. Yu K.S. Kim H.S. Lee A. Jang I.J. Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of DWP14012, a Novel Potassium-Competitive Acid Blocker, in Healthy Male Subjects Aliment. Pharmacol. Ther. 2018 48 206 218 10.1111/apt.14818 29863280
35. Labenz J. Armstrong D. Lauritsen K. Katelaris P. Schmidt S. Schütze K. Wallner G. Juergens H. Preiksaitis H. Keeling N. A Randomized Comparative Study of Esomeprazole 40 Mg Versus Pantoprazole 40 Mg for Healing Erosive Oesophagitis: The EXPO Study Aliment. Pharmacol. Ther. 2005 21 739 746 10.1111/j.1365-2036.2005.02368.x 15771760
36. Richter J.E. Kahrilas P.J. Johanson J. Maton P. Breiter J.R. Hwang C. Marino V. Hamelin B. Levine J.G. Esomeprazole Study Investigators Efficacy and Safety of Esomeprazole Compared with Omeprazole in GERD Patients with Erosive Esophagitis: A Randomized Controlled Trial Am. J. Gastroenterol. 2001 96 656 665 10.1111/j.1572-0241.2001.03600.x 11280530
37. Sharma P. Shaheen N.J. Perez M.C. Pilmer B.L. Lee M. Atkinson S.N. Peura D. Clinical Trials: Healing of Erosive Oesophagitis with Dexlansoprazole MR, a Proton Pump Inhibitor with a Novel Dual Delayed-Release Formulation–Results from Two Randomized Controlled Studies Aliment. Pharmacol. Ther. 2009 29 731 741 10.1111/j.1365-2036.2009.03933.x 19183157
38. Kinoshita Y. Miwa H. Kasugai K. Efficacy of Esomeprazole Compared With Omeprazole in Reflux Esophagitis Patients—A Phase III, Multicenter, Randomized, Double-Blind, Parallel-Group Trial- Nihon Shokakibyo Gakkai Zasshi 2013 110 234 242 23381211
39. Kalaitzakis E. Björnsson E. A review of esomeprazole in the treatment of gastroesophageal reflux disease (GERD) Ther. Clin. Risk Manag. 2007 3 653 663 18472988
40. Jones R. Patrikios T. The effectiveness of esomeprazole 40 mg in patients with persistent symptoms of gastro-oesophageal reflux disease following treatment with a full dose proton pump inhibitor Int. J. Clin. Pract. 2008 62 1844 1850 10.1111/j.1742-1241.2008.01923.x 19166433
41. Velanovich V. Vallance S.R. Gusz J.R. Tapia F.V. Harkabus M.A. Quality of life scale for gastroesophageal reflux disease J. Am. Coll. Surg. 1996 183 217 224 8784314
42. Sandhu D.S. Fass R. Current Trends in the Management of Gastroesophageal Reflux Disease Gut Liver 2018 12 7 16 10.5009/gnl16615 28427116
43. Sachs G. Shin J.M. Munson K. Scott D.R. Gastric Acid-Dependent Diseases: A Twentieth-Century Revolution Dig. Dis. Sci. 2014 59 1358 1369 10.1007/s10620-014-3104-8 24852882
44. Kung Y.M. Hsu W.H. Wu M.C. Wang J.W. Liu C.J. Su Y.C. Kuo C.H. Kuo F.C. Wu D.C. Wang Y.K. Recent Advances in the Pharmacological Management of Gastroesophageal Reflux Disease Dig. Dis. Sci. 2017 62 3298 3316 10.1007/s10620-017-4830-5 29110162
45. Sakurai K. Suda H. Fujie S. Takeichi T. Okuda A. Murao T. Hasuda K. Hirano M. Ito K. Tsuruta K. Short-Term Symptomatic Relief in Gastroesophageal Reflux Disease: A Comparative Study of Esomeprazole and Vonoprazan Dig. Dis. Sci. 2019 64 815 822 10.1007/s10620-018-5365-0 30415407
46. Oshima T. Arai E. Taki M. Kondo T. Tomita T. Fukui H. Watari J. Miwa H. Randomised Clinical Trial: Vonoprazan Versus Lansoprazole for the Initial Relief of Heartburn in Patients with Erosive Oesophagitis Aliment. Pharmacol. Ther. 2019 49 140 146 10.1111/apt.15062 30589965
47. Xiao Y. Zhang S. Dai N. Fei G. Goh K.L. Chun H.J. Sheu B.S. Chong C.F. Funao N. Zhou W. Phase III, Randomised, Double-Blind, Multicentre Study to Evaluate the Efficacy and Safety of Vonoprazan Compared with Lansoprazole in Asian Patients With Erosive Oesophagitis Gut 2020 69 224 230 10.1136/gutjnl-2019-318365 31409606
48. Wiklund I. Review of the quality of life and burden of illness in gastroesophageal reflux disease Dig. Dis. 2004 22 108 114 10.1159/000080308 15383750
49. Wahlqvist P. Karlsson M. Johnson D. Carlsson J. Bolge S.C. Wallander M.A. Relationship between symptom load of gastrooesophageal reflux disease and health-related quality of life, work productivity, resource utilization and concomitant diseases: Survey of a US cohort Aliment. Pharmacol. Ther. 2008 27 960 970 10.1111/j.1365-2036.2008.03671.x 18315585
50. Lee S.W. Chang C.M. Chang C.S. Kao A.W. Chou M.C. Comparison of presentation and impact on quality of life of gastroesophageal reflux disease between young and old adults in a Chinese population World J. Gastroenterol. 2011 17 4614 4618 10.3748/wjg.v17.i41.4614 22147968
51. Lee S.W. Lien H.C. Chang C.S. Peng Y.C. Ko C.W. Chou M.C. Impact of body mass index and gender on quality of life in patients with gastroesophageal reflux disease World J. Gastroenterol. 2012 18 5090 5095 10.3748/wjg.v18.i36.5090 23049219
52. Irvine E.J. Quality of Life Assessment in Gastro-Oesophageal Reflux Disease Gut 2004 53 (Suppl. S4) iv35 iv39 10.1136/gut.2003.034314 15082612
53. Shaker R. Castell D.O. Schoenfeld P.S. Spechler S.J. Nighttime heartburn is an under-appreciated clinical problem that impacts sleep and daytime function: The results of a gallup survey conducted on behalf of the american gastroenterological association Am. J. Gastroenterol. 2003 98 1487 1493 10.1111/j.1572-0241.2003.07531.x 12873567
54. Farup C. Kleinman L. Sloan S. Ganoczy D. Chee E. Lee C. Revicki D. The impact of nocturnal symptoms associated with gastroesophageal reflux disease on health-related quality of life Arch. Intern. Med. 2001 161 45 52 10.1001/archinte.161.1.45 11146697
55. Kinoshita Y. Hongo M. Efficacy of twice-daily rabeprazole for reflux esophagitis patients refractory to standard once-daily administration of PPI: The Japan-based TWICE study Am. J. Gastroenterol. 2012 107 522 530 10.1038/ajg.2012.19 22433921
56. Chey W.D. Mody R.R. Izat E. Patient and physician satisfaction with proton pump inhibitors (PPIs): Are there opportunities for improvement? Dig. Dis. Sci. 2010 55 3415 3422 10.1007/s10620-010-1209-2 20397047
57. Jansen J.B. Klinkenberg-Knol E.C. Meuwissen S.G. De Bruijne J.W. Festen H.P. Snel P. Lückers A.E. Biemond I. Lamers C.B. Effect of long-term treatment with omeprazole on serum gastrin and serum group A and C pepsinogens in patients with reflux esophagitis Gastroenterology 1990 99 621 628 10.1016/0016-5085(90)90946-X 2199288
58. Echizen H. The first-in-class potassium-competitive acid blocker, vonoprazan fumarate: Pharmacokinetic and pharmacodynamic considerations Clin. Pharmacokinet. 2016 55 409 418 10.1007/s40262-015-0326-7 26369775
59. Kojima Y. Takeuchi T. Sanomura M. Higashino K. Kojima K. Fukumoto K. Takata K. Sakamoto H. Sakaguchi M. Tominaga K. Does the novel potassiumcompetitive acid blocker vonoprazan cause more hypergastrinemia than conventional proton pump inhibitors? A multicenter prospective crosssectional study Digestion 2018 97 70 75 10.1159/000484217 29393198
60. Putcha N. Drummond M.B. Wise R.A. Hansel N.N. Comorbidities and Chronic Obstructive Pulmonary Disease: Prevalence, Influence on Outcomes, and Management Semin. Respir. Crit. Care Med. 2015 36 575 591 26238643
61. Lee A.L. Goldstein R.S. Gastroesophageal Reflux Disease in COPD: Links and Risks Int. J. Chron. Obstruct. Pulmon. Dis. 2015 10 1935 1949 10.2147/COPD.S77562 26392769
62. Kim N. Lee S.W. Cho S.I. Park C.G. Yang C.H. Kim H.S. Rew J.S. Moon J.S. Kim S. Park S.H. The prevalence of and risk factors for erosive oesophagitis and non-erosive reflux disease: A nationwide multicentre prospective study in Korea Aliment. Pharmacol. Ther. 2008 27 173 185 10.1111/j.1365-2036.2007.03561.x 17973646
63. Yamamichi N. Mochizuki S. Asada-Hirayama I. Mikami-Matsuda R. Shimamoto T. Konno-Shimizu M. Takahashi Y. Takeuchi C. Niimi K. Ono S. Lifestyle factors affecting gastroesophageal reflux disease symptoms: A cross-sectional study of healthy 19864 adults using FSSG scores BMC Med. 2012 10 45 10.1186/1741-7015-10-45 22554226
64. Huo X. Souza R.F. Acid burn or cytokine sizzle in the pathogenesis of heartburn? J. Gastroenterol. Hepatol. 2013 28 385 387 10.1111/jgh.12103 23441717
